Speaker Profile
M.D., Ph.D., CEO, LuminoDx
Biography
Yipeng Wang is an experienced biotechnology entrepreneur and scientist with expertise in molecular diagnostics, biomarker development, and precision medicine. He focuses on translating innovative biomarker discoveries into clinically actionable diagnostic solutions.
His current work centers on developing and commercializing liquid biopsy technologies, including HepatoTrack™, a blood-based molecular diagnostic test for noninvasive monitoring of liver transplant rejection. He also leads initiatives in advanced proteomics, molecular assay development, and biomarker discovery to support pharmaceutical research and clinical development.
With a multidisciplinary background spanning medicine, molecular biology, and biotechnology, he is passionate about bridging scientific innovation and clinical applications to improve patient care.
Talk
HepatoTrack: Advancing Liver Transplant Management Through Liquid Biopsy
Liver transplant rejection remains a major clinical challenge, requiring timely and accurate monitoring. This presentation introduces HepatoTrack™, a novel blood-based microRNA diagnostic test designed to assess rejection risk noninvasively. Clinical validation results and ongoing efforts to integrate liquid biopsy into routine post-transplant care will be discussed.
Clinical Dx Showcase:
LuminoDx
LuminoDx is a San Diego-based molecular diagnostics company developing innovative liquid biopsy tests, initially focused on liver disease and transplantation. The company is expanding into cancer prognosis and minimal residual disease (MRD) monitoring through proteomics, ctDNA mutation and methylation profiling, and other molecular biomarkers.
Session Abstract – PMWC 2027 Silicon Valley
The PMWC 2027 Data Applications in Clinical Diagnostics Showcase will provide a 15-30 minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Neurodegenerative
Davos of Precision Medicine
PMWC 2027 Program
January 27–29, 2027 · Santa Clara Convention Center
Swipe speakers · Tap a card for sessions →
In a few words.
PMWC is indeed The Davos of Biotech
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
